207 related articles for article (PubMed ID: 27441843)
1. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.
Matsuda Y; Sugiura K; Hashimoto T; Ueda A; Konno Y; Tatsumi Y
PLoS One; 2016; 11(7):e0159661. PubMed ID: 27441843
[TBL] [Abstract][Full Text] [Related]
2. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
3. A novel method for predicting the efficacy of topical drugs on onychomycosis: A comparison of efinaconazole and luliconazole.
Masumoto A; Takagi M; Sugiura K; Matsuda Y; Nakamura S; Tatsumi Y
J Mycol Med; 2022 Aug; 32(3):101259. PubMed ID: 35255449
[TBL] [Abstract][Full Text] [Related]
4. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
5.
Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
Monti D; Mazzantini D; Tampucci S; Vecchione A; Celandroni F; Burgalassi S; Ghelardi E
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332076
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
Tabata Y; Takei-Masuda N; Kubota N; Takahata S; Ohyama M; Kaneda K; Iida M; Maebashi K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
Kawai M
Med Mycol J; 2019; 60(3):71-74. PubMed ID: 31474693
[TBL] [Abstract][Full Text] [Related]
9. Topical and device-based treatments for fungal infections of the toenails.
Foley K; Gupta AK; Versteeg S; Mays R; Villanueva E; John D
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012093. PubMed ID: 31978269
[TBL] [Abstract][Full Text] [Related]
10. Preparation and
Lee BC; Pangeni R; Na J; Koo KT; Park JW
Drug Deliv; 2019 Dec; 26(1):1167-1177. PubMed ID: 31738083
[TBL] [Abstract][Full Text] [Related]
11. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
[TBL] [Abstract][Full Text] [Related]
12. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Seidl HP; Jäckel A; Müller J; Schaller M; Borelli C; Polak A
Mycoses; 2015 Oct; 58(10):610-9. PubMed ID: 26334024
[TBL] [Abstract][Full Text] [Related]
13. Infected nail plate model made of human hair keratin for evaluating the efficacy of different topical antifungal formulations against Trichophyton rubrum in vitro.
Lusiana ; Reichl S; Müller-Goymann CC
Eur J Pharm Biopharm; 2013 Aug; 84(3):599-605. PubMed ID: 23419812
[TBL] [Abstract][Full Text] [Related]
14. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
Elsayed MM
J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
[TBL] [Abstract][Full Text] [Related]
15. Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.
Adigun CG; Vlahovic TC; McClellan MB; Thakker KD; Klein RR; Elstrom TA; Ward DB
J Drugs Dermatol; 2016 Sep; 15(9):1116-20. PubMed ID: 27602975
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis].
Shimamura T; Miyamae A; Imai A; Hirayanagi K; Iwanaga T; Kubota N; Shibuya K
Med Mycol J; 2016; 57(4):J141-J147. PubMed ID: 27904059
[TBL] [Abstract][Full Text] [Related]
18. [Distribution of Luliconazole in Nail Plate by In Vitro Permeation and Efficacy by Zone of Inhibition Test after Treatment of Luliconazole Nail Solution].
Shimamura T; Miyamae A; Arai M; Minemura A; Nozawa A; Kubota N
Med Mycol J; 2016; 57(1):J19-25. PubMed ID: 26936348
[TBL] [Abstract][Full Text] [Related]
19. Efinaconazole (Jublia) for the treatment of onychomycosis.
Gupta AK; Simpson FC
Expert Rev Anti Infect Ther; 2014 Jul; 12(7):743-52. PubMed ID: 24850511
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.
Tatsumi Y; Yokoo M; Senda H; Kakehi K
Antimicrob Agents Chemother; 2002 Dec; 46(12):3797-801. PubMed ID: 12435679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
